INO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
298.9K
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
298.9K
0
0
0
0
Operating Expenses
19.8M
+6.4%
18.6M
-15.2%
21.9M
+25.6%
17.5M
-17.6%
21.2M
R&D
10.6M
-1.9%
10.8M
-23.1%
14.1M
+37.1%
10.3M
-23.0%
13.3M
SG&A
9.2M
+18.1%
7.8M
-1.0%
7.9M
+9.2%
7.2M
-8.4%
7.9M
Operating Income
-19524930
-4.8%
-18624522
+15.2%
-21949993
-25.6%
-17476601
+17.6%
-21210455
EBITDA
-19202896
-4.9%
-18302488
+15.4%
-21633149
-26.2%
-17136404
+17.9%
-20860257
Net Income
-49204789
-718.4%
-6012458
+69.5%
-19682798
-622.8%
3.8M
+108.3%
-45496672
EPS (Basic)
$-0.50
-614.3%
$-0.07
+75.0%
$-0.28
-566.7%
$0.06
+106.9%
$-0.87
EPS (Diluted)
$-0.50
-614.3%
$-0.07
+75.0%
$-0.28
-566.7%
$0.06
+106.9%
$-0.87
Shares (Diluted)
98.6M
+20.8%
81.6M
+18.1%
69.1M
+19.3%
57.9M
+11.0%
52.2M
Inovio Pharmaceuticals (INO) — Financials